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This review focuses on the role of natural killer (NK) cells in
acute and chronic hepatitis B virus (HBV) and hepatitis C
virus (HCV) infections and on cytokine-mediated mecha-
nisms that contribute to alterations in NK cell phenotype
and function.
Natural killer (NK) cells are traditionally regarded as
ﬁrst-line effectors of the innate immune response, but
they also have a distinct role in chronic infection. Here,
we review the role of NK cells against hepatitis C virus
(HCV) and hepatitis B virus (HBV), two agents that cause
acute and chronic hepatitis in humans. Interest in NK
cells was initially sparked by genetic studies that
demonstrated an association between NK cell–related
genes and the outcome of HCV infection. Viral hepatitis
also provides a model to study the NK cell response to
both endogenous and exogenous type I interferon (IFN).
Levels of IFN-stimulated genes increase in both acute and
chronic HCV infection and pegylated IFNa has been the
mainstay of HCV and HBV treatment for decades. In
chronic viral hepatitis, NK cells display decreased pro-
duction of antiviral cytokines. This phenotype is found in
both HCV and HBV infection but is induced by different
mechanisms. Potent antivirals now provide the opportu-
nity to study the reversibility of the suppressed cytokine
production of NK cells in comparison with the antigen-
induced defect in IFNg and tumor necrosis factor-a pro-
duction of virus-speciﬁc T cells. This has implications for
immune reconstitution in other conditions of chronic
inﬂammation and immune exhaustion, such as human
immunodeﬁciency virus infection and cancer. (Cell Mol
Gastroenterol Hepatol 2015;1:578–588; http://dx.doi.org/
10.1016/j.jcmgh.2015.09.004)
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without priming target cells that do not express major his-
tocompatibility complexes (MHCs).1,2 With the recent dis-
covery of innate helper-like cells, NK cells are now
considered part of the family of innate lymphoid cells (ILCs),
a classiﬁcation of innate immune cells that mirrors that of
CD8 and CD4 T cells in the adaptive immune system. NK
cells represent the cytotoxic arm of the ILC family and share
expression of the transcription factor eomesodermin withcytotoxic CD8 T cells. Three groups of eomesodermin-
negative helper-like ILCs are the innate counterparts to
adaptive CD4 T cells. ILC1 express the transcription factor
Tbet, have a TH1-like cytokine proﬁle, and provides immu-
nity against intracellular bacteria and parasites. ILC2s
express the transcription factor GATA-3. Their cytokine
proﬁle of interleukin-4 (IL-4), IL-5, IL-9, and IL-13, and
play a role in allergies and antihelminth responses that re-
sembles that of TH2 cells. ILC3 express RORgt and is the
counterpart of TH3 cells.
3–5 An additional classiﬁcation dif-
ferentiates between conventional NK cells and tissue-
resident NK cells. Liver-resident NK cells use Tbet rather
than eomesodermin and are only weakly cytotoxic. As
strong tumor necrosis factor-a (TNFa) producers, they are
closer to ILC1 than to conventional NK cells.6,7 They were
initially described in mice, but an equivalent population of
liver-resident NK cells has recently also been reported in
humans.8
In viral infections, NK cells exert rapid innate responses
by exerting cytotoxicity against infected target cells and by
releasing antiviral cytokines. By killing immature dendritic
cells and secreting proinﬂammatory cytokines and chemo-
kines, NK cells support the priming of T cells and orchestrate
the recruitment of other immune cells to the site of infec-
tion.9 These mechanisms enhance the adaptive arm of the
immune response, which ultimately clears the infection and
provides immune memory and protection upon reinfection.
This classic division of labor between the innate and adap-
tive immune systems has recently been blurred, with some
NK cells exhibiting features of adaptive cells, such as
antigen-speciﬁc clonal expansion and contraction and
development of long-lived memory. This feature was initially
described for a subpopulation of liver-resident NK cells in
mice that confers transferrable immunity against chemical
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(CMV) is now known to induce memory NK cells via inter-
action of the viral glycoprotein with an NK cell receptor,12
and human CMV has been shown to induce oligoclonal ex-
pansions and epigenetic modiﬁcations of human NK cells
with memory-like functions.13–15 A detailed review of the
mechanisms of NK cell memory has been published
elsewhere.16
NK cell responses are controlled by a large number of
activating and inhibitory cell surface receptors. Activating
receptors include natural cytotoxicity receptors (NKp30,
NKp44, and NKp46), lectin-like receptors (NKG2C, NKG2D)
that are expressed as dimers with CD94, and signaling
lymphocyte activation molecule (SLAM) family receptors
(2B4, CRACC, NTB-A), among others.17 Inhibitory receptors
include killer-cell immunoglobulin-like receptors (KIRs) and
NKG2A/CD94. Receptors are expressed in a combinatorial
manner, which creates an estimated 6000 to 30,000 pheno-
typically distinct NK cell subpopulations in the blood of each
individual and an even larger diversity among individuals.18
In the absence of infection, inﬂammation, and other
diseases, NK cells mostly receive inhibitory signals.
Expression of inhibitory receptors is genetically deter-
mined.18 It is thought that KIRs have coevolved with their
ligands, the human leukocyte antigens (HLA), to ensure
maintenance of self-tolerance. NK cells become activated
when signals from inhibitory receptors decrease, such as
when the expression of KIR-binding MHC molecules on
virus-infected cells decreases, or when signals from acti-
vating receptors increase, such as when antibody-coated
viral antigens and/or stress-induced ligands on infected
cells are recognized. NK cells also respond to inﬂammatory
cytokines such as type I interferons (IFNa and IFNb), IL-2,
IL-12, IL-15 and IL-18 that are commonly released in
response to virus infections.19 NK cell activation increases
the expression level of activating receptors,18 thereby
allowing NK cells to acquire a more responsive state in the
context of infection and inﬂammation.
This review discusses evidence for an antiviral role of
NK cells in hepatitis C virus (HCV) infection, and then de-
scribes alterations of NK cell function in chronic HCV and
hepatitis B virus (HBV) infection that are consistent with an
increased regulatory role at the expense of antiviral func-
tion. The reversibility of this phenotype is discussed.
What Is the Role of Natural Killer Cells
in Subclinical and Acute Hepatitis C
Virus Infection?
Hepatitis C virus (HCV) is an RNA virus of the Flavivir-
idae family that establishes persistent infection in the ma-
jority of infected patients. A potential role for NK cells in
viral hepatitis was ﬁrst suggested by genetic studies that
described a higher odds ratio of spontaneous HCV clear-
ance20 and IFN-treatment-induced HCV clearance21 in
KIR2DL3þ patients who are homozygous for HLA-C1 alleles
as compared with patients who are homozygous or het-
erozygous for HLA-C2 alleles. HLA-C1 and HLA-C2 represent
two groups of HLA-C alleles that differ in two amino acids intheir respective HLA-Cw a1 domains. Because the interac-
tion between KIRs on NK cells with HLA molecules on target
cells plays a key role in NK cell inhibition, it has been sug-
gested that the KIR2DL3/HLA-C1 compound genotype re-
sults in a lower activation threshold of NK cells, thereby
allowing faster NK cell activation compared with less
favorable genotypes. This is supported by data in an in vitro
inﬂuenza A virus infection model that demonstrate a larger
HLA-C–regulated NK cell subset with more rapid NK cell
IFN-g secretion and cytotoxicity in HLA-C1 than in HLA-C2
homozygous patients.22
An increased prevalence of KIR2DL3/HLA-C1 homozy-
gosity is also observed in injection drug users who remain
aviremic and antibody-negative despite high-risk behavior
and frequent HCV exposure.21 The apparent immune pro-
tection in such individuals is associated with KIR2DL3
expression on NK cells23 and with an increased frequency of
activated NK cells.24,25 At the functional level, NK cells in the
blood of exposed uninfected individuals display increased
ex vivo IFNg production24 and increased in vitro cytotox-
icity.25 These results from cross-sectional cohorts are
consistent with data from a prospective study of health care
workers observed after an accidental needlestick.26 Acci-
dental exposure to minute amounts of HCV-containing blood
resulted in a transient increase the frequency of activated
NK cells in the blood and their effector functions (both
cytotoxicity and IFNg production). The magnitude of the NK
cell response correlated with that of the subsequent HCV-
speciﬁc T-cell response. This likely represents an early
innate response to an abortive or rapidly contained and
cleared infection, because neither viremia nor HCV-speciﬁc
antibodies are detected.26
Collectively, these studies demonstrate that NK cells are
sensitive biomarkers of subclinical HCV exposure. While it is
possible that NK cells—along with other components of the
innate immune system—contribute to viral containment in
this setting, it is obvious that innate immune responses on
their own cannot clear the infection once high-level HCV
viremia is established. Data from prospectively studied
humans and experimentally infected chimpanzees demon-
strate that high-level HCV viremia persists for weeks despite
induction of a large set of intrahepatic interferon-stimulated
genes (ISGs).27,28 This immune response is initiated in the
cytoplasm and in endosomes of infected cells by the pattern
recognition receptors protein kinase, retinoic acid inducible
gene-I, and toll-like receptor 3 (TLR3).29 Downstream sig-
nals, mediated by interferon regulatory factor 3 (IRF3) and
nuclear factor-kB, result in the transcription of the
IFNb gene. IFNb is released from infected cells, binds to the
IFNa/b receptor (IFNAR1 and IFNAR2) on neighboring cells,
and induces a diverse ISG set that includes many antiviral
and proinﬂammatory genes.30 However, owing to HCV’s
elaborate strategies to escape from IFN responses,29,31 there
is no decrease in viremia, just a plateau. Patients are typi-
cally clinically asymptomatic during this period and do not
seek medical attention.
The onset of clinically symptomatic acute hepatitis with
increased alanine aminotransferase levels occurs 8 to
10 weeks after infection. Without treatment, two-thirds of
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associated with a 2–3 log10 reduction in viral titer. Because
liver biopsies are clinically not indicated in the acute phase
of hepatitis C, the intrahepatic effector responses respon-
sible for the decrease in viremia have not been studied in
patients. However, data from biopsy tissues of experimen-
tally infected chimpanzees have clearly shown that the
decrease in viremia coincides with an increase in intra-
hepatic IFNg-mRNA levels.27,28,32
The relative contribution of T cells and NK cells to IFNg
production and antiviral response is not known at this time.
Whereas the appearance and maintenance of HCV-speciﬁc
T-cell responses in the blood, in particular CD4 T-cell pro-
liferation and cytokine production, are the best predictors of
viral clearance,32–37 NK cells are also activated and display
increased cytotoxicity and IFNg production.38–40 Pelletier
et al39 recently reported a correlation between the magni-
tude of T-cell response and the peripheral blood NK cell
response in the acute phase of HCV infection, and Kokor-
delis et al40 found that NK cells from patients who later
cleared the infection have a greater antiviral effect in vitro
than NK cells from patients who developed chronic HCV
infection. This opens the interesting question of whether the
increased NK cell activity in acute HCV infection is an in-
dependent event or is triggered by CD4 T-cell–derived IL-2.
The latter would render NK cells ampliﬁers and even
downstream effectors of the virus-speciﬁc T-cell response.
How Does Chronic Hepatitis C
Virus infection Alter Natural Killer
Cell Function?
NK cells are activated not just in acute but also in chronic
HCV infection. They express increased levels of CD69 and
HLA-DR, indicating recent and more distant stimulation,
respectively, and increased levels of NKp30,41 NKp44,22
NKp46,22,42,43 NKG2A, NKG2D,44 and the IL-2 receptor b
chain CD122.22 Increased NKG2C expression has also been
reported,22,44 but has now been attributed to oligoclonal
expansion of a highly differentiated NK cell subset during
prior HCMV infection.45 NK cell activation is inﬂuenced by
location, as NK cells are generally more activated in liver
than in blood, even in uninfected individuals.41 NK cell
activation is also inﬂuenced by additional factors; for
example, NKp46 levels are strongly associated with female
gender and Caucasian race.46
While exciting new information on liver-resident NK
cells and NK cell memory is emerging in the general NK cell
ﬁeld, data on these topics are still sparse in HCV infection.
This is mostly due to the limited number (about 100,000) of
lymphocytes that can be isolated from subcutaneous liver
biopsy tissues and the lack of liver tissue from uninfected
controls. Only a single study performed a side-by-side
comparison of intrahepatic NK cells from surgically resec-
ted liver tissue of patients with HCV infection and unin-
fected controls (who underwent cholecystectomy).41 In that
study, HCV infection was associated with an increased fre-
quency (compared with uninfected livers) of intrahepatic
NK cells that shared some phenotypic and functionalfeatures with the unique liver-resident NK cell population
that has been proposed to represent the human equivalent
to mouse memory NK cells in subsequent studies.8,47 This
raises the interesting, but as yet unstudied question of
whether HCV infection affects NK cells with memory func-
tions in the liver.
Chronic HCV infection leaves a distinct signature also on
peripheral blood NK cells, which has now been conﬁrmed by
several independent studies. Most remarkable is a di-
chotomy in effector functions that is characterized by
increased cytotoxicity (evidenced by increased degranula-
tion and production of tumor necrosis factor-related
apoptosis-inducing ligand [TRAIL]) and, upon in vitro
stimulation with IL-12/IL-15 or IL-12/IL-18, decreased
production of antiviral cytokines (IFNg and TNFa).22,44,48,49
This is unexpected because the size of the CD56bright subset,
which constitutes about 10% of peripheral blood NK cells in
uninfected individuals, doubles in chronic HCV infection.
CD56bright NK cells are known to produce large amounts of
IFNg and TRAIL with little perforin/granzyme-mediated
cytotoxicity.50,51 Most of the remaining NK cells belong to
the more mature CD56dim subset. These cells contain high
levels of perforin and granzyme, but can also rapidly pro-
duce chemokines and cytokines.50 The altered subset dis-
tribution and overall decrease in the number of intrahepatic
and blood NK cells44,48,52,53 should therefore not result in
the selective decrease in cytokine production.
What is the mechanism underlying these divergent
effector functions? Increasing signaling via NKp30, NKp44,
and NKp46 may directly contribute to the increase in NK
cell cytotoxicity because these molecules are natural cyto-
toxicity receptors (NCRs) and NCRþ NK cells have been
shown to release more perforin/granzyme containing
granules and exert greater in vitro antiviral effect than
NCR NK cells.40,46 Increased expression of the activating
receptor NKG2D and its ligands may also contribute to NK
cell cytotoxicity,54 as may decreased expression of the
inhibitory receptor NKG2A.
Cytokine-dependent signals are thought to play a major
role in the increase in NK cell cytotoxicity and decrease in
NK cell cytokine production in chronic HCV infection
(Figure 1). This is evidenced by increased ex vivo levels of
signal transducer and activator of transcription 1 (STAT1), a
key molecule of IFNa signaling in NK cells. Because STAT1
itself is an ISG, increased STAT1 levels are consistent with
type I IFN-mediated signaling in chronic HCV infection. This
is supported by increased ex vivo levels of phosphorylated
STAT1 and decreased levels of phosphorylated STAT4 in NK
cells of HCV-infected patients compared with NK cells of
uninfected patients.55,56 Chronic exposure to virus-induced
type I IFN can explain the NK cell phenotype of increased
cytotoxicity and decreased cytokine production because
induction of cytotoxicity and production of IFNg require
differential STAT1/4 signaling.
Based on a model initially proposed by Miyagi et al57 for
lymphocytic choriomeningitis virus (LCMV) infection, NK
cells produce IFNg in the early phase of a virus infection
because of their constitutively high STAT4 expression.
Chronic exposure to type I IFN results in increased
Figure 1. Altered natural killer (NK) cell function in chronic
hepatitis C virus (HCV) infection. NK cells are activated in
HCV infection with greater signaling from activating than
inhibitory receptors (see text for details). Polarization of NK
cell function toward increased (solid line) cytotoxicity and
decreased (dotted line) production of antiviral cyto-
kines22,44,55 is driven by type I interferon (IFN), produced by
Toll-like receptor 7 (TLR7)-stimulated plasmacytoid dendritic
cells62,63 and other nonparenchymal cells (not pictured).
Mechanisms mediated by interleukin-10 (IL-10), which
contribute to this NK cell phenotype in hepatitis B virus (HBV)
infection, may also be operative in HCV infection because
virus-speciﬁc T cells that secrete IL-10 have been demon-
strated in the liver.113 IL-10 is also directly induced in NK cells
via interaction of the inhibitory NKG2A/CD94 receptor with
human leukocyte antigen E (HLA-E) on HCV-infected hepa-
tocytes.74 HLA-E is thought to be stabilized by an endoge-
nously processed HCVcore peptide and therefore expressed
at increased levels.75 Suboptimal production (dotted line) of
IL-18 and IL-2 may further decrease IFNg production by NK
cells. Monocytes from patients with chronic HCV infection
produce less IL-18 than monocytes from healthy controls
upon coculture with HCV-replicating hepatocytes and NK
cells.70 HCV-speciﬁc CD4 T-cell responses and IL-2 pro-
duction are reduced in HCV infection.114
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phosphorylation,57 increased STAT1-dependent cytotoxicity
(with TRAIL itself being an ISG), and decreased STAT4-
dependent IFNg production.58 The observations of
increased pSTAT1/pSTAT4 ratio and increased levels of the
ISGs STAT1 and TRAIL in NK cells in chronic HCV infection
therefore provide compelling evidence that type I IFN is
produced locally in HCV infection even though it is detectable
only rarely and at exceedingly low levels in the serum.59–61
Candidates for type I IFN production are nonparenchymal
cells, such as liver-resident macrophages (Kupffer cells),
plasmacytoid dendritic cells, and liver sinusoidal endothelial
cells. Kupffer cells were identiﬁed as a local source of IFNa
by immune-staining of liver sections.61 Plasmacytoiddendritic cells were shown to respond to short-range
transfer of HCV RNA-containing exosomes from hepatoma
cells with TLR7-induced production of type I IFN in in vitro
experiments.62,63 Finally, primary human liver sinusoidal
endothelial cells and immortalized liver endothelial cells
were shown to produce type I IFN after internalization of
HCV and stimulation of TLR7 and retinoic acid-inducible gene
1 (RIG-I).64 The dichotomy of increased cytotoxicity and
decreased cytokine production by NK cells is exacerbated
when HCV-infected patients undergo IFN-based
therapy.55,65–67 This NK cell phenotype can be recapitulated
when peripheral blood mononuclear cells of uninfected in-
dividuals are exposed to IFNa in vitro.22,66
In addition to the local increase in type I IFN, a relative
decrease in IL-12, IL-18, and IL-2 production is thought to
contribute to the suppressed cytokine production of NK
cells in chronic HCV infection (see Figure 1). HCV is known
to activate the inﬂammasome in monocytes and macro-
phages in an infection-independent process that requires
recognition of viral RNA by endosomal TLR7. This can be
achieved by clathrin-mediated uptake and uncoating of HCV
particles and release of their RNA in endosomes.68,69 It can
also be achieved by cell-to-cell transfer of RNA as shown in
cocultures of primary human monocytes with hepatoma
cells that contain replicating subgenomic HCV RNA but do
not release infectious HCV particles.70 Inﬂammasome acti-
vation results in secretion of IL-18 and IL-1b in this cocul-
ture model,70 and both cytokines are also detected at
increased levels in the blood of patients with acute HCV
infection.71 IL-18 stimulates IFNg production and down-
regulation of HCV replication by NK cells in cocultures
with HCV-replicon cells and monocytes.70 Interestingly,
monocytes from healthy IL-18 production and IFNg-medi-
ated antiviral activity of NK cells improve when monocytes
from HCV-infected patients are replaced with monocytes
from healthy blood donors in this system.70 These data
show that suboptimal monocyte activation and IL-18 pro-
duction contribute to the defective cytokine production of
NK cells in chronic HCV infection. A lack of IL-2 may further
contribute to the decreased cytokine production of NK cells.
This scenario in chronic HCV infection clearly contrasts with
acute HCV infection where serum IL-18 levels peak,71 and
where HCV-speciﬁc CD4 T-cell responses33,36 and IFNg
producing NK cell responses40 are strong and predictive of
HCV clearance.
In addition to monocytes, monocyte-derived dendritic
cells have a reduced cytokine response in HCV infection.
Speciﬁcally, they produce less IL-15 than those of healthy
controls, which results in reduced expression of MHC class
I-related chain A and B (MICA/B) and in reduced NK cell
stimulation via the MICA/B ligand NKG2D.72,73 Conversely,
NK cells from HCV patients do not activate dendritic cells as
much as NK cells from healthy donors.74 This is thought to
be due to stabilization of HLA-E on HCV-infected hepato-
cytes by an endogenously processed HCVcore peptide.74,75
HLA-E binds to the inhibitory NKG2A/CD94 receptor on
NK cells and induces IL-10 and TGF-b production.74
What are the consequences of an NK cell phenotype that
is biased toward an increase in cytotoxicity and a decrease
Figure 2. Altered natural killer (NK) cell function in chronic
hepatitis B virus (HBV) infection. Activated NK cells display
a similar functional phenotype of increased cytotoxicity
(increased tumor necrosis factor-related apoptosis-inducing
ligand [TRAIL] production, conserved cytotoxicity) and
decreased cytokine production in HBV infection as seen in
chronic hepatitis C virus (HCV) infection,44 but it appears to
be induced by transforming growth factor b (TGFb) and
interleukin-10 (IL-10) rather than by type I interferon (IFN).
Neutralization of TGFb and IL-10 normalizes NK cell function
in vitro.84 IL-10–producing regulatory B cells have been
described in HBV infection and may contribute to the
phenotype.87 In contrast to HCV infection, increased
interferon-stimulated gene (ISG) levels are not a typical
feature of chronic HBV infection.81
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antiviral effects both via perforin/granzyme-mediated
cytotoxicity and via IFNg-mediated down-regulation of
HCV replication in in vitro models.66,76,77 As initially pro-
posed by Guidotti and Chisari,78 a cytokine-mediated anti-
viral effect may be more efﬁcient than cytotoxicity in the
infected liver because secreted cytokines can reach many
infected hepatocytes whereas cytotoxicity requires a 1:1
interaction between cells.78 The altered functional pheno-
type of NK cells in chronic HCV infection may therefore
facilitate chronic inﬂammation via killing of infected cells
but not allow viral clearance due to impaired IFNg pro-
duction. Because suppressed cytokine secretion is also a key
characteristic of the T-cell response in chronic HCV infec-
tion,79 this may be a general mechanism to dampen the
immune response of the host and to ameliorate disease
pathogenesis.
Does the Altered Natural Killer Cell
Phenotype Extend to Other Forms of
Chronic Hepatitis?
To answer the question whether the altered NK cell
phenotype represents a speciﬁc mechanism of HCV persis-
tence or a general host response to decrease immunopa-
thology, it is interesting to study NK cells in other viral
infections. HBV is a good example because it belongs to a
different family of viruses and employs different mecha-
nisms to establish persistence.31 Most HCV infections occur
in immune-competent adults whereas most HBV infections
occur during the neonatal period and in early childhood
when immune responses are less mature and the inﬂam-
matory response is lower than in adulthood. One of the most
striking differences to HCV is the absence of detectable ISG
responses, even in the acute phase of hepatitis.80,81 This
suggests that type I IFN—the main factor that drives the
increase in NK cell cytotoxicity and the decrease in IFNg
production in HCV infection—does not play a major role in
HBV infection.
However, despite the differential type I IFN response, al-
terations in the NK cell phenotype and function in HBV
infection are strikingly similar to those in HCV infection. The
overall percentage of NK cells in the peripheral blood
mononuclear cell population is decreased,44,82,83 with a rela-
tive and absolute increase of the CD56bright NK cell subset.84
Likewise, NK cells display increased expression of activating
receptors such as NKp30, NKp46, and NKG2C43 with
decreased expression of the inhibitory marker NKG2A.43,52
As in HCV infection, NK cells of chronic HBV patients
have a reduced capacity to produce IFNg compared with
healthy controls.44,84,85 Conversely, NK cell cytotoxicity is
maintained, and the percentage of TRAIL-expressing
CD56bright NK cells is increased. This altered NK cell
phenotype is already apparent in pediatric patients after
perinatal acquisition of HBV infection from their mothers.86
Although NK cell phenotype and function are similar in
HCV and HBV infection, the underlying causative mecha-
nisms are different (Figure 2). In HBV infection, alterations
in NK cell function appear to be induced by IL-10 and TGFbrather than IFNa.84 Accordingly, the cytokine-induced di-
chotomy in NK cell effector functions increases during
phases of increased disease activity with increased IL-10
serum levels.84 Some of the IL-10 may be derived from
regulatory B cells, which have been demonstrated in HBV
infection.87 This NK cell phenotype can be recapitulated by
in vitro exposure to IL-10, which suppresses IFNg produc-
tion without altering cytotoxicity and IL-10 production.
Conversely, blockade of IL-10 and/or TGFb restores IFNg
production of both CD56bright and CD56dim NK cells
in vitro.84
Thus, the common theme of preserved NK cell cytotox-
icity and impaired IFNg production is found in both chronic
HBV and HCV infections. Like HCV, HBV is sensitive to the
antiviral effects of IFNg. IFNg from adoptively transferred
HBV-speciﬁc CD8þ T cells88 and from therapeutically acti-
vated NK cells has been shown to down-regulate HBV
replication in transgenic mouse models.89 The lack of IFNg
production by NK cells in chronic HBV infection may
therefore result in reduced viral control and inability to clear
HBV, and the preserved cytotoxicity appears to contribute to
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IL-10 promoter are associated with increased IL-10 pro-
duction, and with increased disease severity and progression
in chronic HBV infection.90,91 Furthermore, liver inﬂamma-
tion correlates with TRAIL expression on NK cells and
TRAIL-expressing NK cells are enriched in the liver.92
What could be the reason for the preserved NK cell
cytotoxicity in chronic viral hepatitis? NK cell cytotoxicity
may serve a regulatory role, aimed at controlling virus-
speciﬁc T-cell responses. HBV-speciﬁc T cells up-regulate
TRAIL death receptor 2 (TRAIL-R2), which renders them
susceptible to apoptosis by TRAIL-expressing NK cells.
Increased TRAIL-R2 expression is speciﬁcally observed on
intrahepatic HBV-speciﬁc CD8þ T cells in close contact with
TRAIL-expressing NK cells, and it correlates with the HBV
titer.93 In contrast, the majority of T cells of other speciﬁcity
do not up-regulate TRAIL-R2, which indicates that T-cell
receptor stimulation by cognate antigen rather than
bystander activation is the underlying mechanism. Indeed,
in vitro depletion of NK cells from peripheral blood mono-
nuclear cells of HBV-infected patients increases HBV-
speciﬁc but not CMV-speciﬁc CD8þ T-cell responses.93 A
similar regulatory role of NK cells is also found in the mouse
model of chronic LCMV-induced hepatitis.94 NK cells spe-
ciﬁcally kill LCMV-speciﬁc CD4 T cells in a perforin-
dependent manner, and a reduced CD4 T-cell response is
associated with a secondary reduction of the LCMV-speciﬁc
CD8 T-cell response.94 In addition, activated CD8 T cells
become targets of NKG2Dþ NK cells because they up-
regulate NKG2D ligands in LCMV infection.95 Conse-
quently, depletion of NK cells restores CD4 T-cell help and
thereby enhances the LCMV-speciﬁc CD8 T-cell response,94
and blocking of the activating receptor NKG2D on NK cells
directly increases the frequency of functioning, antigen-
speciﬁc CD8 T cells.95 It has therefore been proposed that
NK cells function as “rheostats” for virus-speciﬁc T-cell re-
sponses and that therapeutic targeting of NK cells may have
differential effects based on the degree of virus-driven T-cell
exhaustion.96
Are Altered Immune Functions
Reversible by Antiviral Therapy?
The observed down-regulation of IFNg production by
both NK cells and T cells in HCV and HBV infections raises
the interesting question of whether their impaired function
can be restored by antiviral therapy. As described in the
previous sections, the suppression of NK cell IFNg produc-
tion is cytokine-driven—that is, driven by an excess of IFNa,
IL-10, and transforming growth factor b (TGFb) and by a
relative lack of IL-12, IL-18, and IL-2. In contrast, impaired
cytokine production of T cells is attributed to chronic T-cell
receptor stimulation by viral antigens.97 Chronic T-cell re-
ceptor signaling induces inhibitory molecules such as pro-
grammed death 1 (PD-1), T-cell immunoglobulin domain
and mucin domain-3 (Tim-3), and cytotoxic T lymphocyte
antigen 4 (CTLA-4),28,98–101 and promotes an “exhausted”
T-cell phenotype that is also observed in diseases such as
HIV infection and cancer.102Antiviral drugs that rapidly clear HCV infection and
signiﬁcantly reduce HBV viremia provide an excellent clin-
ical model to answer the question of whether the described
changes in NK cell and T-cell function are reversible. IFN-
based treatment regimens are not suitable to answer
these questions because IFN exerts not only antiviral, but
also immune-modulatory function.103 Speciﬁcally, IFN-
based therapies exacerbate the functional dichotomy of
NK cells toward increased cytotoxic effector functions and
reduced IFNg production,65,67 suppress proliferation of
T-cell and IFNg production of T cells,104,105 and do not fully
restore T-cell effector function even if they achieve viral
clearance.106
In contrast, effective removal of HCV by an IFN-free
regimen of direct-acting antivirals normalizes both pheno-
type and function of NK cells, as now shown in two inde-
pendent studies on combination therapy with the HCV NS5A
inhibitor daclatasvir and the NS3 protease inhibitor asu-
naprevir.49,107 Successful treatment of IFN nonresponders
with this IFN-free regimen is associated with a rapid
decrease of NK cell activation within the ﬁrst 24 hours of
treatment initiation and with normalization of NK cell
phenotype and function by week 8 of the 24-week
regimen.49 Both NK cell cytotoxicity and IFNg production
reach levels that are indistinguishable from those of healthy
controls.49 The concomitant decrease in the frequency of
pSTAT1-expressing NK cells conﬁrms the role of virus-
induced type I IFN for the altered function of NK cell
function in chronic HCV infection.49 This is consistent with a
decrease in the expression level of the ISGs RSAD2, ISG15,
OAS3, and IFIT1 in the total blood leukocyte population.107
The effect of treatment-induced HCV clearance on the T-
cell response is quite different from its effect on NK cells.
Spaan et al107 studied HCV-speciﬁc T-cell responses in
parallel to NK cell responses in ﬁve HLA-A2þ patients
treated with daclatasvir and asunaprevir. They used dex-
tramers of HCV-peptide loaded HLA-A2 molecules to detect
HCV-speciﬁc T cells ex vivo irrespective of their function,
and they report an increase in the frequency of HCV-speciﬁc
T cells in the blood at the treatment time point of week 12.
This is consistent with an earlier report on an increased
ex vivo frequency and improved in vitro proliferation of
HCV-speciﬁc CD8 T cells in 51 HCV patients who were
treated with the protease inhibitor faldaprevir, the HCV
NS5B polymerase inhibitor deleobuvir with or without
ribavirin.108 CD8 T-cell populations that target the sequence
of the infecting virus showed a greater improvement in
in vitro proliferation than those that target sequences in
which the virus had escaped, thus excluding any bias for
preexisting memory T cells. Notably, however, an improved
ex vivo T-cell function has not yet been demonstrated in any
study. In our own study of asunaprevir/daclatasvir-treated
patients,49 we did not observe any recovery of the IFNg
production of HCV-speciﬁc T cells when ex vivo Elispot as-
says with sets of overlapping HCV peptides or minimal
optimal T-cell epitopes were performed (B. Rehermann,
unpublished results). Combined, these early results suggest
that successful IFN-free therapy normalizes phenotype and
function of NK cells, and that it restores the proliferative
584 Barbara Rehermann Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 6capacity but not necessarily the ex vivo effector function of
HCV-speciﬁc T cells.
Treatment of HBV infection differs from treatment of
HCV infection in the sense that IFN-free HBV-speciﬁc anti-
viral regimens signiﬁcantly decrease viremia but do not
induce complete viral clearance.109 This is because the
covalently closed circular form of the HBV DNA persists in
infected cells and serves as its transcriptional template.
Consequently, only very few patients clear HBsAg with long-
term nucleos(t)ide analogue treatment.110 Consistent with
suppression but not complete elimination of HBV, antiviral
therapy with nucleoside analogues corrects some but not all
of the abnormal NK cell parameters. The treatment-induced
decrease in HBV titer is paralleled by normalization of the
percentage of NK cells in peripheral blood mononuclear
cells, the size of the CD56bright NK cell subset, and TRAIL
expression on NK cells. This is associated with reduced liver
inﬂammation. However, consistent with low-level HBV
persistence, there is no or only partial85 restoration of the
NK cells’ capacity to produce IFNg.
As in HCV infection, restoration of T cell responses in
HBV infection is mainly detectable with T cell assays that
require more than a week of in vitro stimulation with viral
antigens. Restoration of T-cell proliferation is greater in
patients who respond to long-term antiviral treatment with
suppression of viremia and loss of HBsAg than in those who
show a decrease in viremia but remain HBsAg positive.111
While the expanded T-cell lines also displayed detectable
IL-2, TNFa, and IFNg responses upon restimulation with
their cognate antigen, T cells remain dysfunctional in ex vivo
assays. Furthermore, even in vitro responses are not
maintained when treatment is discontinued.112 The T-cell
responses of successfully treated patients therefore remain
inferior to those of spontaneously recovered patients.
Collectively, these results suggest, that cytokine-induced
alterations in NK cell function do normalize when the virus
is cleared whereas antigen-induced alterations in T-cell
function are not fully reversible. The observation that
complete normalization of the NK cell phenotype and
function can be achieved in HCV-infected but not in HBV-
infected patients ﬁts the observation that HCV can be
completely cleared with antiviral treatment whereas HBV
persists at low levels.Conclusions and Implications
Research over the past 10 years has expanded our view
on NK cells as both an antiviral and a regulatory immune
cell population in viral hepatitis. Chronic HCV and HBV
infection impose similar alterations on NK cell phenotype
and function. Impairment of IFNg production is observed
for both NK cells and T cells, but induced by different
mechanisms. With new direct-acting antiviral treatment
regimens now available as standard of care for HCV infec-
tion, research into the reversibility of these immune alter-
ations has just begun. An expansion of this new area of
research may provide useful information and strategies for
immunotherapy of infections such as HBV that cannot be
cleared with antiviral drugs alone and require an activeimmune response. Further research in the emerging ﬁeld of
ILC subtypes, liver-resident NK cells, and NK-cell-mediated
memory functions is important to increase our knowledge
of the immune surveillance in the liver and may lead to
novel strategies for immunotherapy of hepatocellular
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